Table 2.
Meta-regression coefficients on the change in major depressive disorder and anxiety disorders logit prevalences over the course of the COVID-19 pandemic in 2020
|
Major depressive disorder |
Anxiety disorders |
||||
|---|---|---|---|---|---|
| B (95% UI) | p value | B (95% UI) | p value | ||
| COVID-19 impact index | 0·4 (0·1 to 0·6) | 0·0044 | 0·4 (0·3 to 0·5) | <0·0001 | |
| Decreasing human mobility* | 0·3 (0·03 to 0·8) | .. | 0·4 (0·1 to 0·8) | .. | |
| Daily SARS-CoV-2 infection rate*† | 6·6 (1·6 to 13·0) | .. | 6·0 (4·3 to 8·1) | .. | |
| Mean or midpoint age | −0·007 (−0·0009 to −0·0006) | 0·0001 | −0·003 (−0·005 to −0·0002) | 0·0001 | |
| Proportion female | 0·1 (0·1 to 0·2) | 0·0001 | 0·1 (0·1 to 0·2) | 0·0001 | |
| Combined depressive and anxiety disorder symptoms | .. | .. | 0·3 (0·1 to 0·4) | 0·0080 | |
| Cross-sectional market research and quota sample | 0·9 (0·6 to 1·2) | <0·0001 | 0·6 (0·2 to 1·0) | 0·0022 | |
Longitudinal market research and quota sample was not significant, and so not included in the final model.
Coefficients are estimated using the B of the COVID-19 impact index multiplied by the B of the COVID-19 impact indicators from the signal model and 95% UIs estimated via multiplying 1000 samples of the posterior distribution of these impact indicator covariates from the indicator model with 1000 samples of the posterior distribution of the indicator coefficient.
Square-root transformed before analysis to correct for positive skew of the COVID-19 impact index coefficient (appendix pp 6–7). UI=uncertainty interval.